Navigation Links
PharmaSURVEYOR's Advanced Drug Safety Service Connects to Microsoft HealthVault
Date:6/11/2009

Personalized drug assessment tool allows members to identify, diagnose and resolve drug side effects and interactions

SEATTLE, June 11 /PRNewswire/ -- PharmaSURVEYOR (http://www.pharmasurveyor.com) announced the integration of their Advanced Drug Safety service with Microsoft HealthVault at the Microsoft Connected Health Conference. PharmaSURVEYOR offers a personalized drug assessment tool designed to show users not only drug-drug interactions but the much more common and often dangerous adverse drug side effects. HealthVault users will be able to run a survey of medications stored in their HealthVault account and PharmaSURVEYOR users will be able to easily create a HealthVault account to store their medications.

"PharmaSURVEYOR is proud to join the growing ecosystem of services connected by HealthVault," said Erick Von Schweber, Executive Co-Chair of PharmaSURVEYOR. "For example, a consumer can download a family member's medications to HealthVault from their pharmacy, run an Advanced Drug Safety survey of those medications and search for any symptoms they're having in PharmaSURVEYOR. Their safety survey will reveal which of their symptoms may actually be side effects, the medications that are more likely causing these and possible substitute drugs that can reduce their risk. The Advanced Drug Safety survey can be used in collaboration with their doctor to identify and diagnose those problems and get them resolved."

PharmaSURVEYOR is the only technology that goes beyond interaction checking to help reveal and reduce combined risks - the risks that add up across the drugs in a regimen even in the absence of chemical interactions. Combined risks were responsible for the death of Heath Ledger and other celebrities, whose drugs did not interact yet combined to lethal effect. While celebrity fatalities are highly visible, adverse effects and interactions are responsible for one in ten deaths in the U.S. - amounting to 4,000 fatalities every week - and have been estimated to cost the U.S. economy over $177 billion annually.

"Drug interaction checkers only flag interaction problems, not combined risks, and they don't help to resolve any problems; PharmaSURVEYOR does!" said Mr. Von Schweber. "PharmaSURVEYOR enables the HealthVault user to perform 'what-if' analyses, like using a spreadsheet, to simulate and evaluate the safety impact of changes to their drug regimen. There's nothing else like it."

About PharmaSURVEYOR

PharmaSURVEYOR, the most advanced drug safety utility, goes far beyond drug interaction checkers, is free to consumers at http://www.pharmasurveyor.com and is available as an online service for integration with healthcare websites, EMR, EHR, PHR and medical applications including Drug Utilization Review, Medication Therapy Management and Medication Reconciliation. For more information, contact Linda Von Schweber at linda@pharmasurveyor.com, (877) 797-8783 x102.

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE PharmaSURVEYOR
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IMAGINE Software Unveils Advanced IMAGINEradiology(TM) Features
2. I-SPY trial offers key insights into locally advanced breast cancer
3. Vaccine shows therapeutic promise against advanced melanoma
4. Study shows drug combination improves outcome for advanced non-small cell lung cancer
5. Chemo Alone Is Best for Advanced Colon Cancer
6. 1 in 10 advanced colon cancer patients worry about prescription drug costs
7. One in ten advanced colon cancer patients worry about prescription drug costs
8. Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
9. More Living Longer With Advanced Colon Cancer
10. Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan
11. Advanced Prostate Cancer Deadlier in Younger Men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Tanya Atagi, MD, is excited to announce ... Atagi Plastic Surgery and Skin Aesthetics. , To tighten skin on the face, ... ultrasound energy. Smoother, younger-looking skin is revealed on all other areas of the body ...
(Date:8/17/2017)... CO (PRWEB) , ... August 17, 2017 , ... ... Moral Injury: The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, ... (war) trauma, to encourage inner healing of memories and achieve forgiveness, through a ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Pot Valet is ... service growing to every city in the state, and soon, every state in the ... their need to visit a cannabis dispensary altogether. , According to Pot ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Centrifugation is more ... in the laboratory that we can no longer do without. And just like a ... of your device. , In this webinar, attendees will learn about the most important ...
(Date:8/17/2017)... Seattle, WA and Lighthouse Point, FL (PRWEB) , ... ... ... Seattle-based healthcare technology firm and Cancer Center Business Development Group, a Florida-based oncology ... that examined patient care data to quantify the dollar amount of attributable savings ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology: